Pembrolizumab + axitinib beyond first-line therapy for mRCC
Author:
- 15 February 2023
- journal article
- research article
- Published by Springer Nature in Nature Reviews Urology
- Vol. 20 (3) , 1
Abstract
No abstract availableKeywords
This publication has 1 reference indexed in Scilit:
- Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell CarcinomaClinical Genitourinary Cancer, 2023